AmplifyBio will advance the quality of human health and save lives by creating next generation platforms, tools, and services to amplify and accelerate the development of therapies and vaccines that will be accessible to millions of people. From concept to commercial.
At AmplifyBio, we excel in preclinical CRO (Contract Research Organization) services, offering a comprehensive suite of solutions to accelerate drug development. Our in vivo and in vitro studies evaluate t toxicology, pharmacokinetics, and clinical and anatomic pathology for traditional small molecule and advanced therapies. These services are complemented by bioanalytics characterization and safety assessments, including biodistribution and immunological impact analysis, ensuring a thorough understanding of the safety profiles for cell and gene therapies.
As an innovative CDMO (Contract Development and Manufacturing Organization) partner, AmplifyBio integrates cutting-edge development, characterization, and manufacturing capabilities for cell and gene therapies and mRNA and plasmid production. We offer seamless support across the therapeutic development lifecycle by combining our scientific expertise with advanced manufacturing technologies.
Partner with AmplifyBio to streamline your journey from concept to commercialization with unmatched efficiency and precision.
AmplifyBio’s combined capabilities span from discovery and development support, including in vivo and in vitro characterization and safety assessments, and an expert team willing to customize the journey to ensure that clients find a development “sandbox” to bring therapeutics from concept to commercial. Whatever the modality being developed or the technology platforms implemented, AmplifyBio is here to accelerate the journey to the clinic.
Partner with the AmplifyBio team if you need a preclinical CRO or commercialization partner for any drug type.
Contact us today for questions or more information about our resources and expertise.
